According to filings with the U.S. Securities and Exchange Commission, Panome Bio is raising $5,973,835.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Edward Weinstein played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Panome Bio
Panome Bio can help you profile and discover biomarkers with our Next-Generation Metabolomics capabilities, comprehensive workflows and personalized data analysis reports. Our Next-Generation Metabolomics platform is making major advancements in the metabolism field by going beyond pairwise comparisons and making complex experiments with large and complicated datasets possible. Cutting-edge technology and computational methods are used to extract only the biologically-relevant chemical compounds to give you a clearer view of phenotype. We provide a global and unbiased view of the metabolome through a suite of complementary LC/MS assays that captures the breadth of diverse metabolites in biological systems. We have the ability to complement your metabolomics data with proteomics to better understand pathways and metabolism through our partnership with Somalogic. Somalogics SomaScan 7K Assay is a high-throughput proteomics assay that screens 7,000 proteins per sample simultaneously.

To learn more about Panome Bio, visit http://panomebio.com/

Contact:
Edward Weinstein, Chief Executive Officer
314-477-4334
https://www.linkedin.com/in/edward-weinstein-415b555/

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.